In CMF regimen, gastric disturbances secondary to oral administration of cyclophosphamide (CTX) frequently induce many patients to take the drug erratically, to lower the daily dose, or to divide it in many administrations. These alterations act as a source of uncertainty in the evaluation of treatment results and may decrease the chemotherapy effectiveness. An i.v. CTX administration is proposed, and the rationale of such a proposal in examined. Data on the mild toxicity of the new schedule are reported.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG.BrusamolinoE.ValagussaP.RossiR.BrugnatelliL.BrambillaC.De LenaM.TanciniG.BajettaE.MusumeciR.VeronesiU.: Combination chemotherapy as an adjuvant treatment in operable breast cancer.N. Engl. J. Med., 294: 405–410, 1976.
2.
BonadonnaG.ValagussaP.: Dose-response effect of CMF in breast cancer.ASCO, 21: C374, 1980.
3.
BroderL.E.CarboneP.P.: Pharmacokinetic considerations in the design of optimal chemotherapeutic regimens for the treatment of breast carcinoma: A conceptual approach.Med. Pediatr. Oncol., 2: 11–27, 1976.
4.
BruceW.R.MeekerB.E.ValerioteF.A.: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo.J. Nat. Cancer Inst., 37: 233–245, 1966.
5.
De LenaM.BrambillaC.MorabitoA.BonadonnaG.: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer.Cancer, 35: 1108–1115, 1975.
6.
RossiA.BonadonnaG.ValagussaP.BanfiA.VeronesiU.: CMF adjuvant program for breast cancer: Five year results.ASCO, 21: C336, 1980.
7.
SkipperH.E.ShabelF.M.MelletL.B.MontgomeryJ.A.WilkoffL.J.LloydH.M.BrocmanR.W.: Implication of biochemical, cytokinetic pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules.Cancer Chemother. Rep., 54: 431–450, 1970.
